

AGVTIPSQRRY (TI-loop) (164-174) SEQ ID NO:17  
C2 domain motifs (186-350)  
HFVWNTFFI (272-280) SEQ ID NO: 11  
C terminal tail related (351-403)  
regions of interest  
TLTKNDLD---FTKTV (PEST domain sequences) (319-351)  
SEQ ID NO: 12  
GDIKVEF---FTKTV (PEST domain sequences) (251-351)  
SEQ ID NO: 13  
DKANKDKAN---FTKTV (PEST) (331-351)  
SEQ ID NO: 14  
RYSDDTDS (pre-PDZ region) (378-385)  
SEQ ID NO: 16  
HTQITKV (PDZ-MAGI-2 interaction domain) (399-403)  
SEQ ID NO: 18

**In the claims:**

AS 80. (Amended) A method for inhibiting aberrant tumor-induced angiogenesis in a patient in need thereof, said method comprising the administration of a PI-3 kinase inhibitor.

~~Please cancel claim 81.~~

Please add the following new claims:

89. The method of claim 80, wherein said PI-3 kinase inhibitor is LY294002.

Ab 90. The method of claim 80, wherein said PI-3 kinase inhibitor is wortmannin.

**REMARKS**

The January 15, 2003 Official Action and the references cited therein have been carefully reviewed. In view of the amendments presented herewith and the following remarks, favorable reconsideration and allowance of this application